A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients
Status: Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Antithrombin alfa (Primary)
- Indications Antithrombin III deficiency
- Focus Therapeutic Use
- 06 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Mar 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jun 2018.
- 09 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2019.